Table II.
Table IIA: UIC clinical and laboratory variables according to the presence or absence of chronic kidney disease and its stage.
| UIC | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Variable | N | CKD not present | N | Stage 1 | N | Stage 2 | N | Stage 3 or higher | p-value |
| Age (years) | 88 | 28(23–38) | 81 | 30(25–41) | 17 | 45 (35 – 50) | 22 | 50(37 – 58) | < 0.0001 |
|
Gender (male : female) |
88 | 67% : 33% | 81 | 43% : 57% | 17 | 41% : 59% | 22 | 32% : 68% | 0.7 |
| MAP (mmHg) | 87 | 86(80 – 92) | 81 | 87 (82 – 93) | 17 | 89 (83 – 94) | 22 | 91(86–99) | 0.1 |
| HC therapy | 87 | 43 (49%) | 81 | 36 (44%) | 17 | 10 (59%) | 21 | 12 (57%) | 0.5 |
| Ferritin (μg/l) | 68 | 347(128–1000) | 56 | 397(176–890) | 11 | 490(226–1134) | 14 | 233 (104–634) | 0.8 |
| Haemoglobin (g/l) | 88 | 90(82–100) | 81 | 83 (78 – 92) | 17 | 77 (65 – 88) | 22 | 76 (69 – 83) | < 0.0001 |
| LDH (u/l) | 79 | 287 (223 – 394) | 69 | 364 (258 – 448) | 17 | 442(338–517) | 19 | 367(315–536) | 0.00031 |
| Indirect bilirubin (μmol/l) | 86 | 30.8 (22.2 – 46.2) | 79 | 46.2(27.4–59.9) | 17 | 29.1(23.9–59.9) | 19 | 37.6(20.5–46.2) | 0.1 |
| AST (u/L) | 69 | 37 (29 – 50) | 72 | 40(31–53) | 17 | 52 (40 – 69) | 16 | 43(34–51) | 0.034 |
| Absolute reticulocyte count (×109/l) | 88 | 354 (232 – 434) | 79 | 345(271–463) | 17 | 353 (260 – 429) | 21 | 243(150–338) | 0.018 |
| Reticulocyte percent (%) | 85 | 12.3(6.9–16.3) | 78 | 14.0(9.7–20.9) | 15 | 11.2(9.2–15.6) | 21 | 12.2(8.1–16.6) | 0.038 |
| Haemoglobin F (%) | 84 | 5.4(2.6–9.6) | 80 | 7.1(3.3–11.3) | 16 | 3.4(2.2–9.1) | 19 | 5.7(2.3–11.3) | 0.4 |
| Haemoglobinuria | 83 | 8 (10%) | 74 | 40 (54%) | 16 | 13 (81%) | 9 | 6 (67%) | < 0.0001 |
| Continuous variables are presented as median values (interquartile range). | |||||||||
| P values < 0.004 are significant after the Bonferonni Correction | |||||||||
| UIC = University of Illinois at Chicago; CKD = chronic kidney disease; MAP = mean arterial pressure; HC = hydroxycarbamide; LDH = lactate dehydrogenase; AST = aspartate transaminase | |||||||||
| Table IIB: Walk-PHaSST clinical and laboratory variables according to presence or absence of chronic kidney disease and its stage. | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Walk-PHaSST | |||||||||
| Variable | N | CKD not present | N | Stage 1 | N | Stage 2 | N | Stage 3 or higher | p-value |
| Age (years) | 126 | 34 (25 – 45) | 96 | 33 (24 – 43) | 17 | 50 (33 – 55) | 36 | 50 (45 – 55) | < 0.0001 |
|
Gender (male : female) |
126 | 48%: 52% | 96 | 47%: 53% | 17 | 47%: 53% | 36 | 50%: 50% | 0.9 |
| MAP (mmHg) | 126 | 82 (78 – 88) | 96 | 83 (77 – 89) | 17 | 88 (83 – 92) | 36 | 91(85 – 102) | < 0.0001 |
| HC therapy | 126 | 56 (44%) | 96 | 43 (45%) | 17 | 8 (47%) | 36 | 14 (39%) | 0.7 |
| Ferritin (μg/l) | 121 | 265(102–607) | 96 | 321 (142–1185) | 17 | 594 (149 – 1023) | 34 | 487(287–1801) | 0.010 |
| Haemoglobin (g/l) | 125 | 92(81–101) | 95 | 85 (75 – 94) | 16 | 82 (69 – 85) | 36 | 79 (62 – 89) | < 0.0001 |
| LDH (u/l) | 117 | 372(305–518) | 89 | 476 (368 – 727) | 16 | 601(437–928) | 34 | 469(316–707) | 0.00016 |
| Indirect bilirubin (μmol/l) | - | Not available | - | Not Available | - | Not Available | - | Not Available | - |
| AST (u/l) | 120 | 39 (29 – 53) | 95 | 50 (37 – 69) | 17 | 49 (42 – 65) | 36 | 47 (33 – 60) | 0.00027 |
| Absolute reticulocyte count (×109/l) | 111 | 246(168–331) | 92 | 269(181–362) | 16 | 266(195–389) | 36 | 216(118–297) | 0.058 |
| Reticulocyte percent (%) | 111 | 8.3(5.9–11.2) | 93 | 10.2(6.9–15.2) | 16 | 10.9(6.4–17.2) | 36 | 8.9(5.2–14.3) | 0.1 |
| Haemoglobin F (%) | 119 | 6.6(2.9–14.7) | 95 | 5.8(2.9–11.8) | 16 | 6.1(2.5–11.9) | 34 | 3.8(1.4–10.6) | 0.3 |
| Haemoglobinuria | 105 | 9 (9%) | 72 | 21 (29%) | 12 | 2 (17%) | 22 | 12 (55%) | < 0.0001 |
Continuous variables are presented as median values (interquartile range).
P values < 0.004 are significant after the Bonferonni Correction
Walk-PHaSST = Walk-Treatment of Pulmonary Hypertension and Sickle Cell Disease with Sildenafil Therapy; CKD = chronic kidney disease; MAP = mean arterial pressure; HC = hydroxycarbamide; LDH = lactate dehydrogenase; AST = aspartate transaminase